Display options
Cite
Wappenschmidt B, Hauke J, Faust U, et al. Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer. Geburtshilfe Frauenheilkd. 2020;80(4):410-429doi: 10.1055/a-1110-0909.
Wappenschmidt, B., Hauke, J., Faust, U., Niederacher, D., Wiesmüller, L., Schmidt, G., Groß, E., Gehrig, A., Sutter, C., Ramser, J., Rump, A., Arnold, N., & Meindl, A. (2020). Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer. Geburtshilfe und Frauenheilkunde, 80(4), 410-429. https://doi.org/10.1055/a-1110-0909
Wappenschmidt, Barbara, et al. "Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer." Geburtshilfe und Frauenheilkunde vol. 80,4 (2020): 410-429. doi: https://doi.org/10.1055/a-1110-0909
Wappenschmidt B, Hauke J, Faust U, Niederacher D, Wiesmüller L, Schmidt G, Groß E, Gehrig A, Sutter C, Ramser J, Rump A, Arnold N, Meindl A. Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer. Geburtshilfe Frauenheilkd. 2020 Apr;80(4):410-429. doi: 10.1055/a-1110-0909. Epub 2020 Apr 21. PMID: 32322110; PMCID: PMC7174002.
Copy Download .nbib Format: NLM
Share it on

Geburtshilfe Frauenheilkd. 2020 Apr;80(4):410-429. doi: 10.1055/a-1110-0909. Epub 2020 Apr 21.

Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer.

Geburtshilfe und Frauenheilkunde

Barbara Wappenschmidt, Jan Hauke, Ulrike Faust, Dieter Niederacher, Lisa Wiesmüller, Gunnar Schmidt, Evi Groß, Andrea Gehrig, Christian Sutter, Juliane Ramser, Andreas Rump, Norbert Arnold, Alfons Meindl

Affiliations

  1. Zentrum familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln, Köln, Germany.
  2. Institut für Medizinische Genetik und Angewandte Genomik, Universität Tübingen, Tübingen, Germany.
  3. Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
  4. Frauenklinik, Sektion Gynäkologische Onkologie, Uniklinik Ulm, Ulm, Germany.
  5. Institut für Humangenetik, Medizinische Hochschule Hannover, Hannover, Germany.
  6. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Campus Großhadern, München, Germany.
  7. Institut für Humangenetik, Universität Würzburg, Würzburg, Germany.
  8. Institut für Humangenetik, Universität Heidelberg, Heidelberg, Germany.
  9. Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, München, Germany.
  10. Institut für klinische Genetik, Technische Universität Dresden, Dresden, Germany.
  11. Universitätsklinikum Kiel, Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany.
  12. Institut für Klinische Molekularbiologie, Universitätsklinikum Kiel, Kiel, Germany.

PMID: 32322110 PMCID: PMC7174002 DOI: 10.1055/a-1110-0909

Abstract

More than ten years ago, the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) set up a panel of experts (VUS Task Force) which was tasked with reviewing the classifications of genetic variants reported by individual centres of the GC-HBOC to the central database in Leipzig and reclassifying them, where necessary, based on the most recent data. When it evaluates variants, the VUS Task Force must arrive at a consensus. The resulting classifications are recorded in a central database where they serve as a basis for ensuring the consistent evaluation of previously known and newly identified variants in the different centres of the GC-HBOC. The standardised VUS evaluation by the VUS Task Force is a key element of the recall system which has also been set up by the GC-HBOC. The system will be used to pass on information to families monitored and managed by GC-HBOC centres in the event that previously classified variants are reclassified based on new information. The evaluation algorithm of the VUS Task Force was compiled using internationally established assessment methods (IARC, ACMG, ENIGMA) and is presented here together with the underlying evaluation criteria used to arrive at the classification decision using a flow chart. In addition, the characteristics and special features of specific individual risk genes associated with breast and/or ovarian cancer are discussed in separate subsections. The URLs of relevant databases have also been included together with extensive literature references to provide additional information and cover the scope and dynamism of the current state of knowledge on the evaluation of genetic variants. In future, if criteria are updated based on new information, the update will be published on the website of the GC-HBOC ( https://www.konsortium-familiaerer-brustkrebs.de/ ).

Keywords: classification of genetic variants; hereditary breast/ovarian cancer; risk genes

Conflict of interest statement

Conflict of Interest/Interessenkonflikt The authors declare that they have no conflict of interest./Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.

References

  1. JAMA Oncol. 2017 Sep 1;3(9):1190-1196 - PubMed
  2. Cancer Res. 2017 Aug 15;77(16):4517-4529 - PubMed
  3. Science. 2000 Jul 21;289(5478):359 - PubMed
  4. Cancer Med. 2018 Apr;7(4):1349-1358 - PubMed
  5. FASEB J. 2011 Nov;25(11):3849-60 - PubMed
  6. J Biol Chem. 2003 Nov 14;278(46):45445-50 - PubMed
  7. Science. 2003 Oct 24;302(5645):639-42 - PubMed
  8. Breast Cancer Res. 2018 Jan 24;20(1):7 - PubMed
  9. Hum Mol Genet. 2016 Jun 1;25(11):2256-2268 - PubMed
  10. Nucleic Acids Res. 2013 Jan;41(Database issue):D962-9 - PubMed
  11. Hum Mutat. 2012 Aug;33(8):1228-38 - PubMed
  12. PLoS One. 2011;6(9):e25632 - PubMed
  13. Int J Mol Sci. 2017 Dec 12;18(12): - PubMed
  14. Am J Hum Genet. 2004 Dec;75(6):1131-5 - PubMed
  15. Hum Mutat. 2013 Oct;34(10):1424-31 - PubMed
  16. Mol Cancer Res. 2011 Mar;9(3):271-9 - PubMed
  17. J Med Genet. 2016 Dec;53(12):800-811 - PubMed
  18. Nucleic Acids Res. 1998 Apr 1;26(7):1653-9 - PubMed
  19. Am J Hum Genet. 2016 May 5;98(5):801-817 - PubMed
  20. EMBO J. 2007 Jul 11;26(13):3238-49 - PubMed
  21. Breast Cancer Res. 2016 Nov 9;18(1):111 - PubMed
  22. Nat Genet. 2010 May;42(5):406-9 - PubMed
  23. Mol Cancer Res. 2003 Jun;1(8):598-609 - PubMed
  24. Am J Hum Genet. 2003 Feb;72(2):270-80 - PubMed
  25. Nat Genet. 2006 Aug;38(8):873-5 - PubMed
  26. Hum Mol Genet. 2012 Jun 15;21(12):2738-44 - PubMed
  27. Hum Mutat. 2005 Jan;25(1):6-17 - PubMed
  28. Breast Cancer Res. 2011 Jul 25;13(4):R73 - PubMed
  29. J Biol Chem. 2005 Jul 29;280(30):27587-94 - PubMed
  30. Nucleic Acids Res. 1997 Oct 1;25(19):3868-74 - PubMed
  31. Int J Biochem Cell Biol. 2011 Mar;43(3):416-22 - PubMed
  32. Cancer. 2001 Aug 1;92(3):479-87 - PubMed
  33. Nat Med. 2008 Aug;14(8):875-81 - PubMed
  34. Gynecol Oncol. 2017 Nov;147(2):375-380 - PubMed
  35. Hum Mutat. 2009 Jan;30(1):12-21 - PubMed
  36. Lancet Oncol. 2015 Aug;16(8):e375-6 - PubMed
  37. J Biol Chem. 2005 Apr 15;280(15):15158-64 - PubMed
  38. J Natl Cancer Inst. 2015 Nov 19;108(2): - PubMed
  39. Mutat Res. 2009 Jul 31;668(1-2):20-6 - PubMed
  40. Breast Cancer Res Treat. 2008 Nov;112(1):159-64 - PubMed
  41. Hum Mutat. 2008 Nov;29(11):1282-91 - PubMed
  42. Breast Cancer Res. 2016 Oct 3;18(1):98 - PubMed
  43. Prog Biophys Mol Biol. 2015 Mar;117(2-3):250-263 - PubMed
  44. Hum Mutat. 2011 Jun;32(6):E2176-88 - PubMed
  45. Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4): - PubMed
  46. Nucleic Acids Res. 2006 May 22;34(9):2833-43 - PubMed
  47. N Engl J Med. 2014 Aug 7;371(6):497-506 - PubMed
  48. Front Oncol. 2018 Oct 25;8:480 - PubMed
  49. Nature. 2014 Sep 4;513(7516):120-3 - PubMed
  50. Hum Mutat. 2009 Nov;30(11):1543-50 - PubMed
  51. Am J Hum Genet. 2009 Oct;85(4):427-46 - PubMed
  52. Nat Struct Mol Biol. 2010 Oct;17(10):1255-9 - PubMed
  53. Cancer Res. 2017 Jun 1;77(11):2789-2799 - PubMed
  54. Am J Med Genet A. 2004 Apr 30;126A(3):272-7 - PubMed
  55. BMC Med Genet. 2013 Jan 09;14:5 - PubMed
  56. DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1039-47 - PubMed
  57. Hum Mol Genet. 2014 Jul 15;23(14):3666-80 - PubMed
  58. Clin Cancer Res. 2007 Jul 1;13(13):3789-95 - PubMed
  59. Clin Chem. 2014 Feb;60(2):341-52 - PubMed
  60. Curr Biol. 2009 Mar 24;19(6):524-9 - PubMed
  61. Br J Cancer. 2004 Feb 23;90(4):866-73 - PubMed
  62. Genet Med. 2015 May;17(5):405-24 - PubMed
  63. Hum Mutat. 2006 Feb;27(2):163-72 - PubMed
  64. Fam Cancer. 2016 Apr;15(2):215-9 - PubMed
  65. Mol Cell Biol. 1990 Dec;10(12):6565-77 - PubMed
  66. Hum Mol Genet. 2012 Jul 1;21(13):2889-98 - PubMed
  67. N Engl J Med. 2014 Oct 23;371(17):1651-2 - PubMed
  68. Int J Cancer. 2019 Apr 15;144(8):1962-1974 - PubMed
  69. Mol Cancer Res. 2009 Jul;7(7):1110-8 - PubMed
  70. Nat Genet. 2010 May;42(5):410-4 - PubMed
  71. Oncogene. 2017 Jul 20;36(29):4161-4170 - PubMed
  72. J Clin Oncol. 2015 Sep 10;33(26):2901-7 - PubMed
  73. Mol Cell. 2009 Sep 24;35(6):818-29 - PubMed
  74. Nat Genet. 1998 Dec;20(4):398-400 - PubMed
  75. Hered Cancer Clin Pract. 2014 Apr 08;12(1):10 - PubMed
  76. PLoS One. 2015 Jun 09;10(6):e0127711 - PubMed
  77. Cancer Res. 2003 May 15;63(10):2596-605 - PubMed
  78. Genet Med. 2018 Dec;20(12):1677-1686 - PubMed
  79. Hum Mutat. 2012 Apr;33(4):674-80 - PubMed
  80. Breast Cancer Res Treat. 2016 Jan;155(2):215-22 - PubMed
  81. JAMA Oncol. 2015 Apr;1(1):23-32 - PubMed
  82. Mutagenesis. 2005 Nov;20(6):433-40 - PubMed
  83. DNA Cell Biol. 2013 Jun;32(6):329-35 - PubMed
  84. J Med Genet. 2016 Aug;53(8):548-58 - PubMed
  85. Int J Cancer. 2014 May 1;134(9):2088-97 - PubMed
  86. PLoS One. 2013;8(1):e54772 - PubMed
  87. JAMA Oncol. 2016 Apr;2(4):482-90 - PubMed
  88. Oncogene. 2016 Jul 21;35(29):3796-806 - PubMed
  89. J Med Genet. 2018 Jan;55(1):15-20 - PubMed
  90. EMBO Rep. 2009 Sep;10(9):990-6 - PubMed
  91. Am J Hum Genet. 2004 Oct;75(4):535-44 - PubMed
  92. Breast Cancer Res. 2010;12(6):R109 - PubMed
  93. EMBO Rep. 2012 Feb 01;13(2):135-41 - PubMed
  94. Cancer Res. 2000 Jun 15;60(12):3299-304 - PubMed
  95. Nat Genet. 2011 Aug 07;43(9):879-882 - PubMed
  96. Lancet Oncol. 2015 Feb;16(2):e60-70 - PubMed
  97. Oncogene. 1999 Mar 25;18(12):2163-6 - PubMed
  98. Breast Cancer Res. 2013 Dec 20;15(6):R120 - PubMed
  99. DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1197-205 - PubMed
  100. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10389-94 - PubMed
  101. Cancer Res. 2000 May 1;60(9):2411-8 - PubMed
  102. J Cell Sci. 2010 Apr 1;123(Pt 7):1124-30 - PubMed
  103. Am J Hum Genet. 1998 Mar;62(3):551-61 - PubMed
  104. Genomics. 1998 Apr 1;49(1):103-11 - PubMed
  105. Nat Struct Mol Biol. 2010 Oct;17(10):1247-54 - PubMed
  106. Genetics. 2015 Jun;200(2):413-22 - PubMed
  107. J Med Genet. 2016 Jan;53(1):34-42 - PubMed
  108. J Natl Cancer Inst. 2015 Aug 27;107(11): - PubMed
  109. Nucleic Acids Res. 2004 Jan 02;32(1):169-78 - PubMed
  110. Cell Cycle. 2014;13(14):2262-80 - PubMed
  111. Hum Mutat. 2009 Aug;30(8):1222-30 - PubMed
  112. J Biol Chem. 2002 Dec 13;277(50):48418-26 - PubMed
  113. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9 - PubMed
  114. J Biol Chem. 2009 Aug 7;284(32):21127-31 - PubMed
  115. Oncogene. 2014 Oct 2;33(40):4803-12 - PubMed

Publication Types